Phibro Animal Health Corporation Completes Acquisition of Zoetis’ Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products
Phibro Animal Health (PAHC) has completed the acquisition of Zoetis' medicated feed additive portfolio and certain water-soluble products. The acquisition includes 37+ product lines across approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and a team of over 300 employees. The portfolio is expected to enhance Phibro's profitability, EBITDA margin, and Adjusted Earnings Per Share. The deal expands Phibro's species and product portfolios across cattle, swine, and poultry sectors, complementing their existing lineup of vaccines, nutritional specialties, and mineral nutrition.
Phibro Animal Health (PAHC) ha completato l'acquisizione del portafoglio di additivi alimentari medicati di Zoetis e di alcuni prodotti solubili in acqua. L'acquisizione comprende oltre 37 linee di prodotto in circa 80 paesi, sei stabilimenti di produzione negli Stati Uniti, in Italia e in Cina, e un team di oltre 300 dipendenti. Si prevede che il portafoglio migliori la redditività di Phibro, il margine EBITDA e l'utile per azione rettificato. L'accordo espande le categorie e i portafogli di prodotti di Phibro nei settori del bestiame, suini e pollame, completando la loro gamma esistente di vaccini, specialità nutrizionali e nutrizione minerale.
Phibro Animal Health (PAHC) ha completado la adquisición de la cartera de aditivos alimentarios medicados de Zoetis y ciertos productos solubles en agua. La adquisición incluye más de 37 líneas de productos en aproximadamente 80 países, seis sitios de fabricación en EE. UU., Italia y China, y un equipo de más de 300 empleados. Se espera que la cartera mejore la rentabilidad de Phibro, el margen EBITDA y las ganancias ajustadas por acción. El acuerdo amplía las categorías de especies y productos de Phibro en los sectores de ganado, cerdos y aves de corral, complementando su línea existente de vacunas, especialidades nutricionales y nutrición mineral.
Phibro Animal Health (PAHC)는 Zoetis의 약용 사료 첨가제 포트폴리오 및 일부 수용성 제품을 인수 완료했습니다. 이번 인수에는 약 37개 이상의 제품 라인이 포함되며, 약 80개국에서 거래되고, 미국, 이탈리아, 중국에 6개 제조 시설이 있으며, 300명 이상의 직원이 있습니다. 이 포트폴리오는 Phibro의 수익성, EBITDA 마진 및 조정 주당 순이익을 향상시킬 것으로 기대됩니다. 이번 거래는 Phibro의 소, 돼지, 가금류 부문에 걸친 종 및 제품 포트폴리오를 확장하며, 기존의 백신, 영양 특수 제품 및 미네랄 영양 라인업을 보완합니다.
Phibro Animal Health (PAHC) a finalisé l'acquisition du portefeuille d'additifs alimentaires médicamenteux de Zoetis ainsi que de certains produits solubles dans l'eau. L'acquisition comprend plus de 37 gammes de produits dans environ 80 pays, six sites de fabrication aux États-Unis, en Italie et en Chine, et une équipe de plus de 300 employés. Ce portefeuille devrait améliorer la rentabilité de Phibro, la marge EBITDA et le bénéfice ajusté par action. Cette opération élargit les portefeuilles d'espèces et de produits de Phibro dans les secteurs du bétail, des porcs et de la volaille, complétant leur gamme existante de vaccins, de spécialités nutritionnelles et de nutrition minérale.
Phibro Animal Health (PAHC) hat die Übernahme des Portfolio an medikamentösen Futtermittelzusatzstoffen von Zoetis und bestimmter wasserlöslicher Produkte abgeschlossen. Die Übernahme umfasst über 37 Produktlinien in ca. 80 Ländern, sechs Produktionsstandorte in den USA, Italien und China sowie ein Team von über 300 Mitarbeitern. Es wird erwartet, dass das Portfolio die Rentabilität von Phibro, die EBITDA-Marge und den bereinigten Gewinn pro Aktie verbessert. Das Geschäft erweitert Phibros Arten- und Produktportfolios in den Bereichen Rinder, Schweine und Geflügel und ergänzt deren bestehendes Angebot an Impfstoffen, Ernährungsspezialitäten und Mineralernährung.
- Portfolio expected to boost profitability and EBITDA margin
- Acquisition to be accretive to Adjusted Earnings Per Share
- Expansion into 80 countries with 37+ product lines
- Addition of 6 manufacturing facilities across US, Italy, and China
- Diversification of revenue base
- None.
Insights
This strategic acquisition significantly strengthens Phibro's market position in the animal health sector. The deal brings in 37 product lines across 80 countries, along with 6 manufacturing facilities and 300 employees. The portfolio's global reach and established market presence should provide immediate revenue diversification and operational synergies. The expected boost to profitability, EBITDA margins and adjusted EPS indicates strong financial fundamentals of the acquired assets. The multi-continental manufacturing footprint (US, Italy, China) reduces supply chain risks and provides strategic access to key markets. The integration of medicated feed additives and water-soluble products complements Phibro's existing offerings, potentially creating cross-selling opportunities and enhanced market penetration.
This acquisition positions Phibro strategically in the growing animal health sector, particularly in medicated feed additives. The deal strengthens the company's presence across three major livestock segments - cattle, swine and poultry - providing balanced exposure to different market dynamics. The timing is opportune given the increasing global focus on food security and sustainable livestock production. The expanded product portfolio should help Phibro capitalize on the rising demand for animal health solutions in emerging markets. The addition of water-soluble products also diversifies delivery mechanisms, making the company more competitive in meeting varied customer needs.
“Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro’s species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world,” said Jack C. Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health Corporation. “These products fit Phibro’s core competencies and capabilities while complementing our current lineup of vaccines, nutritional specialties and mineral nutrition.”
The acquisition includes a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the
The portfolio is expected to boost Phibro’s profitability and EBITDA margin and be accretive to its Adjusted Earnings Per Share. Additional financial details will be provided during our Q1 earning call on November 7th.
“This is a win-win-win,” noted Larry Miller, Phibro’s Chief Operating Officer. “For our customers, it broadens the solution options and expertise that Phibro brings to support animal health globally; for consumers, it helps continue to ensure that food is produced safely and sustainably; and for our investors, it expands and diversifies our revenue base, ultimately generating funding to support future investment in additional fast-growing animal health product categories.”
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
Forward-Looking Statements
DISCLOSURE NOTICES
Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031903897/en/
Contact for Phibro Animal Health Corporation
Phibro Animal Health Corporation
Glenn C. David
Chief Financial Officer
+1-201-329-7300
investor.relations@pahc.com
Source: Phibro Animal Health Corporation
FAQ
What products did Phibro Animal Health (PAHC) acquire from Zoetis?
How many manufacturing sites were included in Phibro's (PAHC) acquisition from Zoetis?
What is the expected financial impact of the Zoetis portfolio acquisition on Phibro (PAHC)?
When will Phibro (PAHC) provide additional financial details about the Zoetis acquisition?
